IQVIA (NYSE:IQV) Price Target Cut to $261.00 by Analysts at Stifel Nicolaus

IQVIA (NYSE:IQV) had its price target lowered by research analysts at Stifel Nicolaus from $273.00 to $261.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ target price points to a potential upside of 25.87% from the company’s current price.

A number of other research firms also recently commented on IQV. Deutsche Bank Aktiengesellschaft cut their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Barclays dropped their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Stock Down 1.2 %

IQV stock traded down $2.60 during midday trading on Friday, hitting $207.36. The company’s stock had a trading volume of 216,221 shares, compared to its average volume of 1,378,248. The company has a market cap of $37.64 billion, a PE ratio of 27.24, a P/E/G ratio of 2.15 and a beta of 1.48. The firm’s 50-day moving average is $200.53 and its 200-day moving average is $219.80. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. On average, equities research analysts forecast that IQVIA will post 10.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the third quarter worth $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. increased its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the period. Finally, UMB Bank n.a. raised its position in IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.